News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Press releases

2022

6 April, 2022 Egetis announces that the recruitment target has been met in the Emcitate® Triac Trial II study News Corporate Information Other Corporate Information English IR Optional mfn-cus-emcitate
24 March, 2022 Egetis receives positive EMA opinion for orphan designation of Emcitate for treatment of Resistance to Thyroid Hormone type beta (RTH-β) News Corporate Information Other Corporate Information English IR Optional mfn-cus-emcitate
21 March, 2022 NOTICE OF EXTRAORDINARY GENERAL MEETING IN EGETIS THERAPEUTICS News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional
21 March, 2022 Egetis Therapeutics resolves on a fully guaranteed preferential rights issue of approximately SEK 180 million News Corporate Action Shares Issuance English Regulatory MAR IR Optional
14 March, 2022 Egetis announces participation at upcoming conferences News Corporate Information Other Corporate Information English IR Optional
24 February, 2022 Egetis Therapeutics asks for hugs to increase disease awareness of MCT8 deficiency News English PR Optional mfn-cus-emcitate
18 February, 2022 FDA grants Orphan Drug Designation to Emcitate® for treatment of Resistance to Thyroid Hormone type beta (RTH-β) News Corporate Information Other Corporate Information English IR Optional mfn-cus-emcitate
17 February, 2022 Significant progress towards Emcitate® marketing applications in the US and Europe in 2023 News English Regulatory MAR Report Interim Yearend IR Optional
26 January, 2022 Egetis secures conditional acceptance for Emcitate® as brand name in the US News Corporate Information Other Corporate Information English IR Optional mfn-cus-emcitate
25 January, 2022 Egetis appoints Karl Hård as Head of Investor Relations and Communication News Corporate Information Other Corporate Information English IR Optional mfn-cus-emcitate
18 January, 2022 Egetis concludes that demonstrating treatment effects on T3 levels in MCT8-deficiency could provide a basis for marketing approval for Emcitate® in the US News Corporate Information Other Corporate Information English Regulatory MAR IR Optional mfn-cus-emcitate
11 January, 2022 Egetis Therapeutics gets Notice of Intent to Grant for a new European patent for a combination therapy with Aladote News Corporate Information Other Corporate Information English IR Optional mfn-cus-aladote
Previous

Calendar and upcoming reports

April 15, 2024
Annual Report 2023

May 3, 2024
Interim Report Q1 2024 (7:00am CEST)

Show more events

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com

Cookies
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept all”, you consent to the use of ALL the cookies. However, you may visit "Settings" to provide a controlled consent. Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
Save Accept all